entertainment -WSS

entertainment

author：leisure time 2025-09-30 00:38:04 - browse：153

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Devoted Health’s losses in Medicare Advantage persist

leisure time

WSS

It's time to retire 'poor historian' from clinicians' vocabularies

Top private equity targets in 2023: cardiology, clinical trials, lasers

Venture capitalist Bob Kocher on the state of digital health

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Problems with a popular proposal to regulate AI in health care

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

explore

entertainment

focus

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Amgen, Regeneron, BGI Group and more

United colonoscopy coverage change 'may cost lives,' doctors say

It's time to retire 'poor historian' from clinicians' vocabularies

What does generative AI mean for health care? We asked experts

When prostate cancer spreads, where it goes matters

In Memoriam: Notable people who died in 2023

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Venture capitalist Bob Kocher on the state of digital health

Wikipedia

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Addiction experts warn against a second 'war on drugs'

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Surgery pushed Ben Carson to fame

A protest over insulin prices is seen as a fight for life

Wikipedia

leisure time

leisure time

hotspot